← Leaderboards
Gang Zhou
Augusta University
$5,455,655
Attributed
$7,807,827
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,807,827 · 4
By mechanism
R01$7,807,827 · 4
Top collaborators
- Gary A Piazza5 shared
- Huidong Shi5 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMediatingT-LymphocyteMalignant NeoplasmsT Cell TherapySignal TransductionTumor MicroenvironmentTumor ImmunityCancer ImmunotherapyReportingChimeric Antigen ReceptorGrowthCd4 Positive T LymphocytesImmunotherapyBasePropertyRelapseCellsDesignAnti-Tumor Immune ResponseCd19 GeneIn VitroGenetic TranscriptionPre-Clinical Model
Grant awards (20)
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy$522,742
R01 · FY2025 · CA · contact PI
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy$496,606
R01 · FY2024 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$410,108
R01 · FY2024 · CA · contact PI
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy$512,286
R01 · FY2023 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$423,057
R01 · FY2023 · CA · contact PI
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy$512,286
R01 · FY2022 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$423,057
R01 · FY2022 · CA · contact PI
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy$528,183
R01 · FY2021 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$431,691
R01 · FY2021 · CA · contact PI
Chemotherapy-induced MDSCs and antitumor immunity$347,700
R01 · FY2021 · CA · contact PI
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment$444,328
R01 · FY2020 · CA · contact PI
Chemotherapy-induced MDSCs and antitumor immunity$347,700
R01 · FY2020 · CA · contact PI
Chemotherapy-induced MDSCs and antitumor immunity$337,268
R01 · FY2019 · CA · contact PI
Chemotherapy-induced MDSCs and antitumor immunity$347,700
R01 · FY2018 · CA · contact PI
Chemotherapy-induced MDSCs and antitumor immunity$347,700
R01 · FY2017 · CA · contact PI
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemother$280,125
R01 · FY2016 · CA · contact PI
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemother$280,125
R01 · FY2015 · CA · contact PI
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemother$271,722
R01 · FY2014 · CA · contact PI
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemother$263,318
R01 · FY2013 · CA · contact PI
Reversing tumor-specific CD4+ T-cell tolerance to control relapse after chemother$280,125
R01 · FY2012 · CA · contact PI